Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 5, 2005, Pages 943-948

  Douketis, J D ^a,j   Julian, J A ^a   Kearon, C ^a   Anderson, D R ^f   Crowther, M A ^a   Bates, S M ^a   Barone, M ^b   Piovella, F ^b   Turpie, A G ^a   Middeldorp, S ^d   Van Nguyen, P ^e   Prandoni, P ^c   Wells, P S ^g   Kovacs, M J ^h   MacGillavry, M R ⁱ   Costantini, L ^a   Ginsberg, J S ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

^h LONDON HEALTH SCIENCES CENTRE   (Canada)

ⁱ SLOTERVAART HOSPITAL   (Netherlands)

^j ST JOSEPH S HOSPITAL   (Canada)

more..

Author keywords

Deep vein thrombosis; Estrogen; Hormone replacement therapy; Progestin

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HORMONE SUBSTITUTION; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; BODY MASS; ESTROGEN THERAPY; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK; VEIN THROMBOSIS;

AGED; BODY MASS INDEX; CASE-CONTROL STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; POSTMENOPAUSE; PROGESTINS; PROSPECTIVE STUDIES; RISK; RISK FACTORS; VENOUS THROMBOSIS;

EID: 23844458360     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01268.x     Document Type: Article

References (38)

1. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.
2. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of post-menopausal estrogens. Lancet 1996; 348: 981-3.
3. Pérez Gutthann S, Garcia-Rodriguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997; 314: 796-800.
4. Varas-Lorenzo C, García-Rodríguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Pérez Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol 1998; 149: 387-90.
5. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-7.
6. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S. Postmenopausal hormone replacement therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 2000; 132: 689-96.
7. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321-33.
8. Høibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84: 961-7.
9. Johnson SR. Menopause and hormone replacement therapy. Med Clin North Am 1998; 82: 297-320.
10. Douketis JD, Ginsberg JS, Holbrook AM, Crowther MA, Duku EK, Burrows RH. The risk of venous thromboembolism associated with use of the oral contraceptive and hormone replacement therapy: a re-evaluation. Arch Intern Med 1997; 157: 1522-30.
11. Anonymous. The Canadian Consensus Conference on Contraception. J Soc Obstet Gynecol Can 1998; 20: 27-34.
12. Anonymous. Facts about one-a-month injectable contraceptives: memorandum from a WHO meeting. Bull World Health Org 1993; 71: 677-89.
13. Kaunitz AM. Injectable contraception. New and existing options. Obstet Gynecol Clin North Am 2000; 27: 741-80.
14. Bloemenkamp KWM, Rosendaal FR, Büller HR, Helmerhorst FM, Colly LP, Vandenbroucke JP. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion bias. Arch Intern Med 1999; 159: 65-70.
15. Wallace RB, Sherman BM, Bean JA, Treloar AE, Schlabaugh L. Probability of menopause with increasing duration of amenorrhea in middle-aged women. Am J Obstet Gynecol 1979; 135: 1021-4.
16. Brambilla DJ, McKinlay SM, Johannes CB. Defining the perimenopause for application in epidemiologic investigations. Am J Epidemiol 1994; 140: 1091-5.
17. Kearon C, Ginsberg JS, Hirsh J. The role of ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med 1998; 129: 1044-9.
18. White RH, McGahan JP, Dascbach MM, Hartling RP. Diagnosis of deep-vein thrombosis using Duplex ultrasound. Ann Intern Med 1989; 111: 297-304.
19. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-44.
20. Bernardi E, Prandoni P, Lensing AW, Agnelli G, Guazzaloca G, Scannapieco G, Piovella F, Verlato F, Tomasi C, Moia M, Scarano L, Girolami A. D-dimer testing as an adjunct to ultrasonography in patients with clinically-suspected deep vein thrombosis: prospective cohort study. The Multicentre Italian D-dimer Ultrasound Study Investigators Group. BMJ 1998; 317: 1037-40.
21. Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L, Clement C, Robinson KS, Lewandowski B. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997; 350: 1795-8.
22. Kraaijenhagen RA, Piovella F, Bernardi E, Verlato F, Beckers EA, Koopman MM, Barone M, Camporese G, Potter Van Loon BJ, Prins MH, Prandoni P, Buller HR. Simplification of the diagnostic management of suspected deep vein thrombosis. Arch Intern Med 2002; 162: 907-11.
23. Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Lewandowski B. SimpliRED D-dimer can reduce the need for diagnostic tests. Lancet 1998; 351: 1405-6.
24. Birdwell BG, Raskob GE, Whitsett TL, Durica SS, Comp PC, George JN, Tytle TL, McKee PA. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med 1998; 128: 1-7.
25. Ginsberg JS, Kearon C, Douketis JD, Turpie AGG, Brill-Edwards P, Stevens P, Panju A, Patel A, Crowther M, Andrew M, Massicotte P, Hirsh J, Weitz JI. The use of D-dimer testing and impedance plethysmography in patients with clinical indications of deep vein thrombosis. Arch Intern Med 1997; 157: 1077-81.
26. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-51.
27. Kühl H. Effects of progestagens on haemostasis. Maturitas 1996; 24: 1-19.
28. World Health Organization. Cardiovascular disease and use of oral and injectable progestagen-only contraceptives and combined injectable contraceptives. Contraception 1998; 57: 315-24.
29. Poulter NR, Chang CL, Farley TMM, Meirek O. Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications. Lancet 1999; 354: 1610.
30. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, Rosendaal FR. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527-35.
31. Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, Meijers JC, Bouma BN, Buller HR, Prins MH, Tans G. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomized cross-over study. Lancet 1999; 354: 2036-40.
32. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323: 1-9.
33. Speroff L. Oral contraceptives and arterial and venous thrombosis: a clinician's formulation. Am J Obstet Gynecol 1998; 179: S25-S36.
34. Stanczyk FZ, Roy S. Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception 1990; 42: 67-96.
35. van Baal WM, Emeis JJ, van der Mooren MJ, Kessel H, Kenemans P, Stehower CDA. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study. Thromb Haemost 2000; 83: 29-34.
36. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1995; 273: 199-208.
37. Scarabin PY, Oger E, Plu-Bureau G. Estrogen and Thromboembolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-32.
38. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR. Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 1573-80.